Blood Res 2023; 58(S1):
Published online April 30, 2023
https://doi.org/10.5045/br.2023.2023054
© The Korean Society of Hematology
Correspondence to : Jieun Uhm, M.D., Ph.D.
Division of Hematology & Oncology, Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea
E-mail: jieunuhm@hanyang.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The treatment outcomes of chronic myeloid leukemia in chronic phase (CML-CP) have dramatically improved with comparable life-expectancy to average of general population in tyrosine kinase inhibitor (TKI) era. However, less than a half of patients who started with TKI can remain on frontline TKI. The reasons of switching TKI can be either intolerance or the lack of efficacy. Although a kinase domain (KD) mutation can guide to select salvage TKI from the point of view on the efficacy of TKIs, many factors need to be considered before choosing next-line TKI such as the high-risk features of CML, the adverse events with prior TKI, and the comorbidities of patients. The therapeutic options for CML-CP after failing frontline TKI due to treatment failure or suboptimal responses will be reviewed including allogeneic hematopoietic stem cell transplantation.
Keywords Chronic myeloid leukemia, Tyrosine kinase inhibitors, Ponatinib, Asciminib, Allogeneic hematopoietic stem cell transplantation
Blood Res 2023; 58(S1): S109-S113
Published online April 30, 2023 https://doi.org/10.5045/br.2023.2023054
Copyright © The Korean Society of Hematology.
Jieun Uhm
Division of Hematology & Oncology, Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea
Correspondence to:Jieun Uhm, M.D., Ph.D.
Division of Hematology & Oncology, Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea
E-mail: jieunuhm@hanyang.ac.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The treatment outcomes of chronic myeloid leukemia in chronic phase (CML-CP) have dramatically improved with comparable life-expectancy to average of general population in tyrosine kinase inhibitor (TKI) era. However, less than a half of patients who started with TKI can remain on frontline TKI. The reasons of switching TKI can be either intolerance or the lack of efficacy. Although a kinase domain (KD) mutation can guide to select salvage TKI from the point of view on the efficacy of TKIs, many factors need to be considered before choosing next-line TKI such as the high-risk features of CML, the adverse events with prior TKI, and the comorbidities of patients. The therapeutic options for CML-CP after failing frontline TKI due to treatment failure or suboptimal responses will be reviewed including allogeneic hematopoietic stem cell transplantation.
Keywords: Chronic myeloid leukemia, Tyrosine kinase inhibitors, Ponatinib, Asciminib, Allogeneic hematopoietic stem cell transplantation
Eun-Ji Choi
Blood Res 2023; 58(S1): S29-S36Jieun Uhm, Kyoung Ha Kim, Hyewon Lee, Hawk Kim, Slader Cassandra, Inkyung Joo, Chul Won Jung
Blood Res 2021; 56(1): 31-37Jae Joon Han
Blood Res 2023; 58(S1): S58-S65